Jade Biosciences, Inc. (JBIO)

NASDAQ: JBIO · Real-Time Price · USD

17.03

+0.47 (2.84%)

At close: Dec 19, 2025, 4:00 PM EST

17.00

-0.03 (-0.18%)

After-hours: Dec 19, 2025, 7:57 PM EST

Jade Biosciences Employees

Jade Biosciences had 30 employees as of December 31, 2024.

Employees

30

Change

n/a

Growth

n/a

Revenue / Employee

n/a

Profits / Employee

-$3,131,933

Market Cap

783.45M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	30	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

JBIO News

4 days ago - Jade Biosciences Announces $45 Million Private Placement - GlobeNewsWire
5 weeks ago - Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
5 weeks ago - Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025 - GlobeNewsWire
6 weeks ago - Jade Biosciences to Participate in Upcoming Conferences - GlobeNewsWire
2 months ago - Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025 - GlobeNewsWire
2 months ago - Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases - GlobeNewsWire
2 months ago - Jade Biosciences Announces $135 Million Private Placement - GlobeNewsWire
3 months ago - Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy - GlobeNewsWire